shutterstock-183727541-web
Poprotskiy Alexey / Shutterstock.com
9 March 2015Americas

US FDA approves first biosimilar, keeps quiet on naming standards

The US Food and Drug Administration (FDA) approved Sandoz’s cancer product Zarxio (filgrastim-sndz) on Friday (March 6)—the first biosimilar to be rubber stamped in the US.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
3 July 2015   The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.

More on this story

Americas
3 July 2015   The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.

More on this story

Americas
3 July 2015   The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.